Lexicon Pharmaceuticals Inc (LXRX NASDAQ) stock market data APIs
$1.8072
0.01(0.6%)
as of November 13, 2026
Try our APIs with
free plan!
Lexicon Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Prev. Close
1.8072
Open
1.8165
High
1.8227
Low
1.7114
52 wk Range
1.1-2.68
Market Cap
797 M
Shares Outstanding
445 M
Revenue
38 537 K
EPS
-0.03
Beta
1.084
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lexicon Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lexicon Pharmaceuticals Inc data using free add-ons & libraries
Get Lexicon Pharmaceuticals Inc Fundamental Data
Lexicon Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 38 537 K
- EBITDA: -56 386 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Lexicon Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lexicon Pharmaceuticals Inc News
New
Lexicon Pharmaceuticals Inc (LXRX) (Q3 2026) Earnings Call Highlights: Sonata HCM Data and ...
This article first appeared on GuruFocus. Release Date: November 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Compl...
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago. These fi...
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals, Inc. -- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considera...
Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Cantor Fitzgerald initiated Lexicon Pharmaceuticals (LXRX [https://seekingalpha.com/symbol/LXRX]) at overweight, saying that it is optimistic on...
Get Lexicon Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.